New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
07:02 EDTISISIsis Pharmaceuticals reports final Phase 2 data on ISIS-GCGR Rx
Isis Pharmaceuticals announced the final results from its Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy. In this study, patients in the per protocol population treated with ISIS-GCGRRx in addition to metformin achieved absolute mean reduction in hemoglobin A1c of up to 2.25 percentage points from baseline after only 13 weeks of treatment. Patients receiving placebo had an 0.25 percentage point reduction in HbA1c. In this study, more than half of the PP patients achieved an HbA1c level of less than or equal to 7.0 percent. PP patients treated with ISIS-GCGRRx in this study also achieved a mean reduction of up to 74.9 Ámol/L in fructosamine. In addition, in these patients a mean increase in total GLP-1 of up to 19.97 pmol/L was observed.
News For ISIS From The Last 14 Days
Check below for free stories on ISIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
07:10 EDTISISIsis Pharmaceuticals begins Phase 2 study of candidate for high lipoprotein(a)
Subscribe for More Information
July 16, 2014
07:14 EDTISISIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use